Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · as published 2026-01-23 View official record Methodology

Covered recipient · General Payments record

MARIE EMMA ROBERT

Allopathic & Osteopathic Physicians Pathology Anatomic Pathology & Clinical Pathology

NPI
1932180221
CMS profile
560208
Location
NEW HAVEN, CT

General Payments · PY2018–2024

$113,212.32

  • Reported across 31 records
  • CMS publication 2026-01-23

Latest program year · PY2024

$38,957.50

8 records · 0 disputed

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How these totals are calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

PY2024 · sorted by reported total

By paying entity

PY2024 · sorted by reported total

Paying entityAmountRecords
Takeda Pharmaceuticals U.S.A., Inc. $32,357.50 7
E.R. Squibb & Sons, L.L.C. $6,600.00 1

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2018 $5,514.59 7
PY2021 $5,240.00 1
PY2022 $40,059.00 6
PY2023 $23,441.23 9
PY2024 $38,957.50 8

Payment records · PY2024 (8)

Sorted by paying entity, then date · as published by CMS

Program year 2024 2018202120222023 Record-level detail is published for PY2024; earlier years are summarised in “By program year”.
Paying entity Amount Date Nature of payment Dispute status Published Record ID Source
E.R. Squibb & Sons, L.L.C. $6,600.00 08/13/2024 Consulting Fee Undisputed 01/23/2026 1101827495 CMS
Takeda Pharmaceuticals U.S.A., Inc. $1,380.00 01/19/2024 Consulting Fee Undisputed 01/23/2026 1137663090 CMS
Takeda Pharmaceuticals U.S.A., Inc. $7,820.00 05/06/2024 Consulting Fee Undisputed 01/23/2026 1137663092 CMS
Takeda Pharmaceuticals U.S.A., Inc. $8,050.00 07/26/2024 Consulting Fee Undisputed 01/23/2026 1137663094 CMS
Takeda Pharmaceuticals U.S.A., Inc. $6,440.00 09/04/2024 Consulting Fee Undisputed 01/23/2026 1137663096 CMS
Takeda Pharmaceuticals U.S.A., Inc. $2,802.50 09/06/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Undisputed 01/23/2026 1137663098 CMS
Takeda Pharmaceuticals U.S.A., Inc. $2,875.00 09/25/2024 Consulting Fee Undisputed 01/23/2026 1137663100 CMS
Takeda Pharmaceuticals U.S.A., Inc. $2,990.00 11/04/2024 Consulting Fee Undisputed 01/23/2026 1137663102 CMS

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-01-23
Program years on this page
2018, 2021, 2022, 2023, 2024
Source files
Dataset page · Bulk file · PY2018 , PY2021 , PY2022 , PY2023 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.